You have 9 free searches left this month | for more free features.

canakinumab

Showing 1 - 25 of 48

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Postprandial Hypoglycemia Trial in Basel, Olten (Canakinumab, Placebo (0.9% NaCl))

Recruiting
  • Postprandial Hypoglycemia
  • Canakinumab
  • Placebo (0.9% NaCl)
  • Basel, Switzerland
  • +1 more
Nov 23, 2022

Pancreatic Cancer Trial in New York (Canakinumab, Tislelizumab, Nab-Paclitaxel)

Recruiting
  • Pancreatic Cancer
  • Canakinumab
  • +3 more
  • New York, New York
  • +2 more
Aug 2, 2023

Lung Cancer Trial in Italy (Canakinumab, Placebo)

Terminated
  • Lung Cancer
  • Canakinumab
  • Placebo
  • Rozzano, Milano, Italy, Italy
  • +5 more
Feb 9, 2023

Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF Trial in New York (Canakinumab)

Recruiting
  • Primary Myelofibrosis
  • +4 more
  • Canakinumab
  • New York, New York
    Ruttenberg Treatment Center
Jul 18, 2022

Clonal Cytopenia of Undetermined Significance Trial in Columbus (procedure, drug, other)

Recruiting
  • Clonal Cytopenia of Undetermined Significance
  • Biospecimen Collection
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 12, 2022

Carcinoma, Renal Cell Trial in New York (Spartalizumab, Canakinumab)

Recruiting
  • Carcinoma, Renal Cell
  • New York, New York
    Columbia University Medical Center
May 6, 2022

NSCLC Trial in United States (Canakinumab, Durvalumab, Radiation therapy)

Recruiting
  • Non-small Cell Lung Cancer
  • Canakinumab
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 15, 2022

Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8 Trial in Houston (Canakinumab, Quality-of-Life

Recruiting
  • Lung Carcinoma
  • +12 more
  • Canakinumab
  • Quality-of-Life Assessment
  • Houston, Texas
    M D Anderson Cancer Center
Nov 17, 2021

NSCLC Trial in Worldwide (canakinumab, pembrolizumab)

Completed
  • Non-small Cell Lung Cancer
  • La Jolla, California
  • +28 more
Sep 27, 2022

Coronavirus Infection, Diabetes, Type 2 Trial in Switzerland (Canakinumab, Placebo)

Completed
  • Coronavirus Infection
  • Diabetes Mellitus, Type 2
  • Canakinumab
  • Placebo
  • Aarau, Switzerland
  • +8 more
Sep 7, 2021

NOMID, CINCA Syndrome Trial run by the (Canakinumab)

Terminated
  • NOMID
  • CINCA Syndrome
  • Canakinumab
  • Bethesda, Maryland
    National Institute of Arthritis and Musculoskeletal and Skin Dis
Jun 9, 2021

Skin Inflammation, Allergic Contact Dermatitis Trial in Worcester (drug, other, device)

Recruiting
  • Skin Inflammation
  • Allergic Contact Dermatitis
  • Squaric Acid Dibutyl Ester
  • +12 more
  • Worcester, Massachusetts
    University of Massachusetts Chan Medical School
Sep 6, 2022

Cytokine Release Syndrome in COVID-19-induced Pneumonia Trial (canakinumab)

No longer available
  • Cytokine Release Syndrome in COVID-19-induced Pneumonia
  • canakinumab
  • (no location specified)
Feb 1, 2021

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia Trial in Worldwide (Canakinumab, Placebo)

Completed
  • Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
  • Canakinumab
  • Placebo
  • Birmingham, Alabama
  • +38 more
Jan 21, 2022

Gouty Arthritis Trial in Worldwide (Canakinumab)

Completed
  • Gouty Arthritis
  • Canakinumab
  • Seattle, Washington
  • +44 more
Jun 10, 2021

Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome Trial in Fukuoka-city,

Completed
  • Cryopyrin-associated Periodic Syndromes
  • +3 more
  • canakinumab
  • Fukuoka-city, Fukuoka, Japan
  • +2 more
Sep 23, 2020

MDS Trial in Worldwide (MBG453, NIS793, canakinumab)

Recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +14 more
Jan 23, 2023

Behcet Disease Trial in Istanbul (Canakinumab)

Completed
  • Behcet Disease
  • Canakinumab
  • Istanbul, Turkey
    Novartis Investigative Site
May 28, 2020

Adult-Onset Still´s Disease Trial in Germany (Canakinumab, Placebo)

Terminated
  • Adult-Onset Still´s Disease
  • Canakinumab
  • Placebo
  • Berlin, Germany
  • +13 more
Jul 17, 2020

Non-Small-Cell Lung Trial in Worldwide (Canakinumab, Docetaxel, Placebo)

Completed
  • Non-Small-Cell Lung
  • Canakinumab
  • +2 more
  • Atlanta, Georgia
  • +77 more
Dec 27, 2021

Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers Trial in Bron Cedex, Le Kremlin Bicetre, Paris (canakinumab)

Completed
  • Systemic Juvenile Idiopathic Arthritis
  • Hereditary Periodic Fevers
  • canakinumab
  • Bron Cedex, France
  • +2 more
May 7, 2020

NSCLC Trial in Worldwide (PDR001, Cisplatin, Gemcitabine)

Terminated
  • Non-small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +22 more
Aug 11, 2022

Rheumatoid Arthritis Trial in Worldwide (Canakinumab)

Completed
  • Rheumatoid Arthritis
  • Canakinumab
  • Huntsville, Alabama
  • +50 more
Jun 17, 2021

Systemic Juvenile Idiopathic Arthritis Trial in Worldwide (Canakinumab)

Completed
  • Systemic Juvenile Idiopathic Arthritis
  • Canakinumab
  • Los Angeles, California
  • +72 more
Mar 19, 2019

Periodic Fever Trial in Petah tikva (Canakinumab)

Unknown status
  • Periodic Fever
  • Canakinumab
  • Petah tikva, Israel
    SCMCI
Aug 30, 2018